111 related articles for article (PubMed ID: 35878788)
21. Effects of insulin detemir and NPH insulin on body weight and appetite-regulating brain regions in human type 1 diabetes: a randomized controlled trial.
van Golen LW; Veltman DJ; IJzerman RG; Deijen JB; Heijboer AC; Barkhof F; Drent ML; Diamant M
PLoS One; 2014; 9(4):e94483. PubMed ID: 24739875
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
24. Maternal efficacy and safety outcomes in a randomized, controlled trial comparing insulin detemir with NPH insulin in 310 pregnant women with type 1 diabetes.
Mathiesen ER; Hod M; Ivanisevic M; Duran Garcia S; Brøndsted L; Jovanovic L; Damm P; McCance DR;
Diabetes Care; 2012 Oct; 35(10):2012-7. PubMed ID: 22851598
[TBL] [Abstract][Full Text] [Related]
25. Basal Insulin Analogs versus Neutral Protamine Hagedorn for Type 2 Diabetics.
Fishel Bartal M; Ward C; Refuerzo JS; Ashimi SS; Joycelyn CA; Chen HY; Chauhan SP; Sibai BM
Am J Perinatol; 2020 Jan; 37(1):30-36. PubMed ID: 31430822
[TBL] [Abstract][Full Text] [Related]
26. Different insulin types and regimens for pregnant women with pre-existing diabetes.
O'Neill SM; Kenny LC; Khashan AS; West HM; Smyth RM; Kearney PM
Cochrane Database Syst Rev; 2017 Feb; 2(2):CD011880. PubMed ID: 28156005
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
28. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
[TBL] [Abstract][Full Text] [Related]
29. Revisiting the efficacy of long-acting insulin analogues on adults with type 1 diabetes using mixed-treatment comparisons.
Sanches AC; Correr CJ; Venson R; Pontarolo R
Diabetes Res Clin Pract; 2011 Dec; 94(3):333-9. PubMed ID: 21992870
[TBL] [Abstract][Full Text] [Related]
30. Long-term cost-effectiveness of insulin detemir versus NPH insulin in type 2 diabetes in Sweden.
Smith-Palmer J; Fajardo-Montañana C; Pollock RF; Ericsson A; Valentine WJ
J Med Econ; 2012; 15(5):977-86. PubMed ID: 22563742
[TBL] [Abstract][Full Text] [Related]
31. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes.
Umpierrez GE; Hor T; Smiley D; Temponi A; Umpierrez D; Ceron M; Munoz C; Newton C; Peng L; Baldwin D
J Clin Endocrinol Metab; 2009 Feb; 94(2):564-9. PubMed ID: 19017758
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH.
Valentine WJ; Palmer AJ; Erny-Albrecht KM; Ray JA; Cobden D; Foos V; Lurati FM; Roze S
Adv Ther; 2006; 23(2):191-207. PubMed ID: 16751153
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety among second-generation and other basal insulins in adult patients with type 1 diabetes: a systematic review and network meta-analysis.
Martin ; Zhou Y; Takagi T; Tian YS
Naunyn Schmiedebergs Arch Pharmacol; 2021 Oct; 394(10):2091-2101. PubMed ID: 34319421
[TBL] [Abstract][Full Text] [Related]
35. Safety of insulin glargine use in pregnancy: a systematic review and meta-analysis.
Pollex E; Moretti ME; Koren G; Feig DS
Ann Pharmacother; 2011 Jan; 45(1):9-16. PubMed ID: 21205954
[TBL] [Abstract][Full Text] [Related]
36. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Muthuri S; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
JAMA Intern Med; 2021 May; 181(5):598-607. PubMed ID: 33646277
[TBL] [Abstract][Full Text] [Related]
37. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
38. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
39. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
Danne T; Lüpke K; Walte K; Von Schuetz W; Gall MA
Diabetes Care; 2003 Nov; 26(11):3087-92. PubMed ID: 14578244
[TBL] [Abstract][Full Text] [Related]
40. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
